Last reviewed · How we verify
NCT05437679: CHARTER
Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System
trial testing Blood collection in High Risk Prostate Carcinoma in 9 participants. Terminated before completion.
22 August 2023
Quick facts
| Lead sponsor | Angle plc |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 9 |
| Start date | 5 July 2022 |
| Primary completion | 22 August 2023 |
| Estimated completion | 22 August 2023 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Blood collection — full drug profile →
Conditions studied
- High Risk Prostate Carcinoma — all drugs for High Risk Prostate Carcinoma →
- Biochemically Recurrent Prostate Carcinoma — all drugs for Biochemically Recurrent Prostate Carcinoma →
- Castration-resistant Prostate Cancer — all drugs for Castration-resistant Prostate Cancer →
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Angle plc
Who can join
18 and older, male only, with High Risk Prostate Carcinoma or Biochemically Recurrent Prostate Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed to evaluate the presence and numbers of circulating tumor cells (CTCs) and cancer related gene expression levels in subjects with localized high-risk prostate cancer (HRLPC) and from subjects with non-metastatic disease experiencing biochemical recurrence and castration-resistance (BCRLPC and NMCRPC groups, respectively) who are about to undergo next generation imaging (NGI, such as Axumin® or PSMA PETCT). The investigators will also evaluate subjects with localized indolent prostate cancer who are on active surveillance (AS) as a control population. The CTC and gene expression results will be evaluated for association with disease state and progression and survival.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Redefining cancer care: harnessing circulating tumor cells' potential for improved diagnosis and prognosis.
Janjua D, Chaudhary A, Joshi U, Tripathi T, et al · · 2025 · cited 4× · PMID 40676582 · DOI 10.1186/s12935-025-03883-y
Verify or expand the search:
- PubMed search for NCT05437679
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood collection
Trials testing the same drug.
- NCT07134491 — Peripheral and Intrarenal B Cell Study in Antibody Mediated Transplant Rejection : Phenotypic and Transcriptional Study, · recruiting
- NCT07075107 — Transcriptomic Analysis of Fibroblasts and Blood in Patients With Rare Diseases · NA · not yet recruiting
- NCT06510868 — Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy · recruiting
- NCT06521502 — The APS Phenotyping Study · recruiting
- NCT06373510 — Longitudinal Evaluation of Antibody Kinetics of Vaccinated Patients With Non-mandatory Vaccine Following Administration · NA · not yet recruiting
Other recruiting trials for High Risk Prostate Carcinoma
Currently open trials in the same condition.
- NCT06384222 — Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone · Phase 2 · recruiting
- NCT06204341 — Towards Optimal Treatment for High Risk Prostate Cancer · NA · recruiting
- NCT06461793 — Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy and Hormone Therapy With SpaceOAR TM for Pati · Phase 2 · recruiting
- NCT05004285 — Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis · Phase 3 · active not recruiting
Other Angle plc trials
Trials by the same sponsor.
- NCT03427450 — Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System · completed
- NCT02785731 — Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass. · completed
- NCT02781272 — Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting Wit · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05437679 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Angle plc
- Last refreshed: 5 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05437679.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing